Modifying immune responses to adeno-associated virus vectors by capsid engineering
Molecular Therapy - Methods & Clinical Development · 2023-09 · 30 · 576-592
DOI: 10.1016/j.omtm.2023.08.015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy - Methods & Clinical Development, 2023-09. Verfasst von Martin Bentler und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: German Research Foundation, Federal Ministry of Education and Research Bonn Office, Sächsisches Staatsministerium für Wissenschaft und Kunst.
Abstract (Originalsprache)
De novo immune responses are considered major challenges in gene therapy. With the aim to lower innate immune responses directly in cells targeted by adeno-associated virus (AAV) vectors, we equipped the vector capsid with a peptide known to interfere with Toll-like receptor signaling. Specifically, we genetically inserted in each of the 60 AAV2 capsid subunits the myeloid differentiation primary response 88 (MyD88)-derived peptide RDVLPGT, known to block MyD88 dimerization. Inserting the peptide neither interfered with capsid assembly nor with vector production yield. The novel capsid variant, AAV2.MB453, showed superior transduction efficiency compared to AAV2 in human monocyte-derived dendritic cells and in primary human hepatocyte cultures. In line with our hypothesis, AAV2.MB453 and AAV2 differed regarding innate immune response activation in primary human cells, particularly for type I interferons. Furthermore, mice treated with AAV2.MB453 showed significantly reduced CD8+ T cell responses against the transgene product for different administration routes and against the capsid following intramuscular administration. Moreover, humoral responses against the capsid were mitigated as indicated by delayed IgG2a antibody formation and an increased NAb50. To conclude, insertion of the MyD88-derived peptide into the AAV2 capsid improved early steps of host-vector interaction and reduced innate and adaptive immune responses.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany.
- University of Rouen, INSERM, U1234, Pathophysiology Autoimmunity and Immunotherapy (PANTHER), Normandie University, 76000 Rouen, France.
- Institute for Drug Discovery, University of Leipzig Medical Center, 04103 Leipzig, Germany.
- Center for Scalable Data Analytics and Artificial Intelligence (ScaDS.AI), Dresden/Leipzig, Germany.
- Laboratory for Vector Based Immunotherapy, Fraunhofer Institute for Cell Therapy and Immunology (IZI), 04103 Leipzig, Germany.
- Department of Medicine II, University Cancer Center Leipzig (UCCL), University of Leipzig Medical Center, 04103 Leipzig, Germany.
Förderung
- German Research Foundation
- Federal Ministry of Education and Research Bonn Office
- Sächsisches Staatsministerium für Wissenschaft und Kunst
Zitieren
APA
Bentler, M., Hardet, R., Ertelt, M., Rudolf, D., Kaniowska, D., Schneider, A., Vondran, F. W. R., Schoeder, C. T., Delphin, M., Lucifora, J., Ott, M., Hacker, U. T., Adriouch, S., & Büning, H. (2023). Modifying immune responses to adeno-associated virus vectors by capsid engineering. Molecular Therapy - Methods & Clinical Development, 30, 576-592. https://doi.org/10.1016/j.omtm.2023.08.015
Vancouver
Bentler M, Hardet R, Ertelt M, Rudolf D, Kaniowska D, Schneider A, et al. Modifying immune responses to adeno-associated virus vectors by capsid engineering. Molecular Therapy - Methods & Clinical Development. 2023;30:576-592. doi:10.1016/j.omtm.2023.08.015
BibTeX
@article{Bentler2023,
author = {Bentler, Martin and Hardet, Romain and Ertelt, Moritz and Rudolf, Daniela and Kaniowska, Dorota and Schneider, Andreas and Vondran, Florian W R and Schoeder, Clara T and Delphin, Marion and Lucifora, Julie and Ott, Michael and Hacker, Ulrich T and Adriouch, Sahil and Büning, Hildegard},
title = {Modifying immune responses to adeno-associated virus vectors by capsid engineering},
journal = {Molecular Therapy - Methods & Clinical Development},
year = {2023},
volume = {30},
pages = {576--592},
doi = {10.1016/j.omtm.2023.08.015}
}
EUVIMED